Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
GCP2 CRISPR/Cas9 KO Plasmid (h): sc-404751
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GCP2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the GCP2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: GCP2 Antibody (F-3): sc-377117
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GCP2 CRISPR/Cas9 KO Plasmid (h) | sc-404751 | 20 µg | $397.00 |
Overview
TUBGCP2 encodes gamma-tubulin complex protein 2 (GCP2), a core component of the γ-tubulin ring complex that nucleates microtubules at centrosomes and other microtubule-organizing centers. GCP2 supports mitotic spindle assembly, centrosome maturation, and maintenance of microtubule polarity, thereby influencing cell-cycle progression and chromosome segregation. Through its role in centrosome and spindle integrity, altered TUBGCP2 function is relevant to pathways linked to genomic instability and proliferative phenotypes. Disruption of γTuRC components is frequently investigated in the context of centrosome abnormalities, aneuploidy, and cytoskeletal defects observed across multiple disease-associated cellular states.
GCP2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TUBGCP2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the TUBGCP2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the TUBGCP2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish GCP2 protein expression.
This CRISPR knockout system enables efficient generation of TUBGCP2-deficient cell models for investigation of GCP2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting TUBGCP2 exon(s) critical for GCP2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple TUBGCP2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by GCP2 CRISPR/Cas9 KO Plasmid (h) and GCP2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the TUBGCP2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by GCP2 HDR Plasmid (h) and GCP2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by TUBGCP2 homology arms to support homology-directed repair at defined TUBGCP2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.